ArticleFrontiers in pharmacology2026
2'-deoxyinosine ameliorates multiple sclerosis through modulating Th1/Th2 and Th17/Treg cell balance with potential involvement of AMPK phosphorylation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is an autoimmune and neurodegenerative disease characterized by T lymphocyte infiltration and demyelination that can lead to severe disability without treatment. However, effective treatment for MS remains an unmet need. 2'-deoxyinosine (2'-DI), an endogenous nucleoside, has been implicated in tumorigenesis and immune regulation. This study was performed to investigate whether prophylactic 2'-DI intervention could prevent MS progression and elucidate its action mechanism. Methods: 2'-DI was administered to experimental autoimmune encephalomyelitis mice in vivo and cultured peripheral blood samples from MS patients in vitro, followed by pathological analysis, body weight monitoring, and disease severity assessment. Furthermore, RNA sequencing and serum metabolomics were conducted to explore the underlying regulatory mechanism of 2'-DI. Results: Compared with healthy controls, MS patients exhibited significantly reduced 2'-DI levels in peripheral blood. Prophylactic administration of 2'-DI could prevent the progression of MS and mitigate inflammatory infiltration in the EAE mouse model. Immunomodulatory studies revealed that 2'-DI could decrease Th1 and Th17 cells, whereas increase Treg and Th2 cells. Moreover, 2'-DI could also promote the expression of anti-inflammatory cytokines and transcription factors while inhibiting the expression of pro-inflammatory cytokines and chemokines. Notably, 2'-DI intervention increased AMPK phosphorylation status, suggesting a potential association between elevated AMPK phosphorylation and the 2'-DI-mediated reversal of Th1/Th2 and Th17/Treg cell imbalance. Conclusion: 2'-DI may serve as a promising prophylactic candidate for MS by inhibiting central neuroinflammation and correcting peripheral and central Th1/Th2 and Th17/Treg immune imbalance, with its immunomodulatory effects potentially involving AMPK phosphorylation upregulation, thereby alleviating neuroinflammation and neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.